MedTrace Logo

Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia

NCT04753476 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-05-24

No results posted yet for this study

Summary

In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells. The improvement in clinical, laboratory, and radiological manifestations will be evaluated in treated patients compared with the control group.

Conditions

Interventions

BIOLOGICAL

Injection of Secretome-MSCs

Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) : Day 1: 1 cc every 12 hours Day 2: 1 cc every 12 hours Day 3: 1 cc every 12 hours

DRUG

Standard treatment of Covid-19

Patients will be given Standard treatment of Covid-19 which accordance with National protocol

Sponsors & Collaborators

  • Provincial Government of Central Java, Indonesia

    collaborator UNKNOWN

  • Stem Cell and Cancer Research Indonesia

    lead NETWORK

Principal Investigators

  • Agung Putra, Assoc.Prof · Stem Cell and Cancer Research Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2022-02-01
Completion
2022-03-01

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753476 on ClinicalTrials.gov